Given these encouraging results, Pfizer and BioNTech stated that they were “eager to extend the protection offered by the vaccine to this younger population, subject to obtaining regulatory approval,” as emphasized by Pfizer’s Chairman and CEO, Albert Bourla.
Therefore, the laboratories indicated that they planned to present these findings to the Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regulatory bodies “as soon as possible.” They also specified that they expected to obtain results in children under 5 years of age “by the end of the year.”
COVID-19 vaccine: Are children at greater risk with the Delta variant?
